Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Suzetrigine in ERAS Protocol for DIEP Flap Breast Reconstruction
NCT07839715Phase 3Not yet recruiting
- Sponsor
- Vanderbilt University Medical Center
- Start
- Sep 2026
- Primary completion
- Aug 2027
01
Overview
Phase 3, randomised trial of suzetrigine in postoperative pain (2 arms), sponsored by Vanderbilt University Medical Center. Primary endpoint: Oral Morphine Equivalent at 1 week. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
suzetrigine
03
Conditions
postoperative pain
Beyond the preview
Go deeper on NCT07839715.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07839715.